Eosinophilic Esophagitis Drug Market Size Will Witness Substantial...

Eosinophilic Esophagitis Drug Market Size Will Witness Substantial Growth in the Upcoming Years by 2028

Posted 2025-05-26 11:40:11

Market Overview

Eosinophilic Esophagitis was only officially recognized as a distinct clinical entity in the early 1990s. Since then, awareness has grown exponentially among gastroenterologists and allergists. The disease, marked by chronic and relapsing esophageal inflammation, often overlaps with other allergic conditions such as asthma, eczema, and food allergies.

According to the research report published by Polaris Market Research, the Global Eosinophilic Esophagitis Drug Market Size Is Expected To Reach Us$ 189.7 Million By 2028, at a CAGR of 6.5% during the forecast period.The market now includes both approved drugs and a robust pipeline of biologics and small-molecule inhibitors in various stages of clinical development.

Key Market Growth Drivers

Regulatory Approvals of Targeted Biologic Therapies

A pivotal growth factor is the increasing approval of biologics specifically designed for EoE. For instance, the FDA’s 2022 approval of Dupixent® (dupilumab), a monoclonal antibody from Sanofi and Regeneron, marked a watershed moment for the market. It was the first drug approved specifically for EoE in adults and adolescents, demonstrating significant improvements in both histologic and symptomatic outcomes.

Other biologics in late-stage trials targeting cytokines like IL-5, IL-13, and Siglec-8 promise further advancements and a broader therapeutic landscape.

Growing Prevalence and Diagnosis Rates

The prevalence of EoE is rising worldwide, partly due to heightened awareness and improved endoscopic and biopsy-based diagnostic techniques. According to the American Partnership for Eosinophilic Disorders (APFED), EoE affects approximately 1 in 2,000 people in the U.S., a number likely to increase as awareness spreads in Europe, Asia, and Latin America.

The disease’s strong association with food and environmental allergens makes it a common comorbidity in patients already under allergy surveillance, facilitating earlier detection.

Focus on Chronic Inflammatory and Allergic Diseases

Pharmaceutical companies are increasingly prioritizing chronic allergic conditions as part of broader immunology and inflammation portfolios. EoE, as a prototypical Th2-driven disease, shares mechanistic pathways with asthma and atopic dermatitis—creating synergies for multi-indication drug development and investment.

The increasing burden of chronic inflammatory diseases globally has encouraged governments and private research institutions to fund and support rare disease drug development.

Patient Advocacy and Research Funding

Patient advocacy organizations have been instrumental in raising awareness, funding clinical research, and pushing for expanded insurance coverage for EoE treatments. Campaigns by groups like APFED and CURED (Campaign Urging Research for Eosinophilic Disease) have helped patients gain access to specialists and off-label treatments while pushing the FDA and EMA for faster approvals.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/eosinophilic-esophagitis-drug-market

Market Challenges

Despite optimistic projections, the EoE drug market faces several barriers to widespread adoption and accessibility:

High Cost of Biologic Therapies

One of the major hurdles is the cost of biologic therapies, which can run into tens of thousands of dollars annually per patient. While biologics offer targeted, effective treatment, affordability remains a significant issue—especially in low- and middle-income countries. Insurance coverage can also be inconsistent, leading to delays in treatment initiation.

Limited Treatment Options for Pediatric Populations

Although biologics like Dupixent have been approved for adolescent and adult populations, younger pediatric patients often rely on off-label medications or dietary therapy, which can be difficult to maintain and socially isolating. The lack of FDA-approved treatments for children under 12 remains a concern.

Diagnostic Delays and Misclassification

Despite improved awareness, EoE is often misdiagnosed as GERD (gastroesophageal reflux disease), due to overlapping symptoms such as swallowing difficulty and chest discomfort. Delayed diagnosis can lead to unnecessary treatments and progression to esophageal narrowing or fibrosis.

Adverse Effects and Treatment Adherence

Topical steroids, though effective, can have side effects such as esophageal candidiasis and reduced adrenal function with long-term use. Additionally, adherence to elimination diets—often used in pediatric cases—poses challenges due to social and nutritional limitations.

Regional Analysis

North America

North America, particularly the U.S., dominates the EoE drug market, accounting for over 45% of global revenue in 2024. This is due to early regulatory approvals, high healthcare expenditure, and robust reimbursement systems. Research institutions and pharmaceutical companies have collaborated effectively to advance drug pipelines and conduct clinical trials across multiple states.

Europe

Europe holds the second-largest share of the market. Countries such as Germany, the UK, and France have seen a rise in EoE diagnosis due to the widespread adoption of upper GI endoscopy and increased training of healthcare professionals. However, differences in healthcare reimbursement policies may influence the uptake of biologics across European markets.

Asia-Pacific

Asia-Pacific is expected to grow at the fastest rate through 2030, fueled by increased healthcare access, rising prevalence of allergic diseases, and expanding awareness campaigns. Japan and South Korea are leading the region in terms of clinical research and adoption of advanced therapies, while India and China present large untapped patient populations.

Latin America and Middle East & Africa

These regions currently hold a smaller share of the global market but are witnessing gradual growth. Limited access to advanced diagnostics and biologic therapies is a constraint, though improving healthcare infrastructure and collaborations with international NGOs could support future expansion.

Key Companies in the EoE Drug Market

Several global pharmaceutical and biotech companies are driving innovation in the EoE treatment space:

Sanofi & Regeneron Pharmaceuticals

Their joint product Dupixent® is the first and only FDA-approved biologic for EoE, revolutionizing care for adolescents and adults. The companies are actively pursuing pediatric indications and exploring additional uses for eosinophilic GI disorders.

AstraZeneca

Through its acquisition of Alexion Pharmaceuticals, AstraZeneca has gained a foothold in rare disease treatments and is reportedly exploring novel targets for chronic allergic conditions like EoE and EGIDs (eosinophilic gastrointestinal diseases).

Allakos Inc.

Allakos is developing lirentelimab (AK002), an anti-Siglec-8 antibody aimed at reducing eosinophil activity in the GI tract. Though initial trials faced setbacks, updated formulations and improved endpoints could reestablish its place in the pipeline.

Takeda Pharmaceuticals

Takeda is conducting trials for Etrasimod and other anti-inflammatory agents initially aimed at ulcerative colitis, with secondary investigations into EoE. Their strong presence in gastroenterology positions them well for strategic entry into the EoE segment.

Arena Pharmaceuticals (a Pfizer company)

Now under Pfizer, Arena is researching small-molecule modulators of immune pathways implicated in EoE. Their focus on oral agents may provide alternatives to injectable biologics, potentially improving patient adherence.

Other notable players in the EoE drug development pipeline include Revolo Biotherapeutics, Celgene (a Bristol Myers Squibb company), and GlaxoSmithKline.

Conclusion

The Eosinophilic Esophagitis Drug Market is on a transformative path, fueled by cutting-edge biologic therapies, rising global disease awareness, and a commitment to improving outcomes in chronic allergic conditions. While challenges like cost, diagnostic delays, and treatment gaps for younger patients persist, the increasing focus of global biopharma on rare immune-mediated diseases offers hope for a future where EoE is not only manageable but potentially curable.

More Trending Latest Reports By Polaris Market Research:

Opioid Market

Ovarian Cancer Market

Hemodialysis and Peritoneal Dialysis Market

Hospital Supplies Market

India Diagnostic Services Market

Migraine Drugs Market

Nephrology and Urology Devices Market

Orphan Drugs Market

Orthobiologics Market

Prostate Cancer Treatment Market

Sickle Cell Disease Treatment Market